Global Hereditary Angioedema Therapeutics Market Size study, by Treatment Type, Route of Administration, Age Group, Distribution Channel and Regional Forecasts 2022-2032

Description

Global Hereditary Angioedema (HAE) Therapeutics Market is valued approximately at USD 4.1 billion in 2023 and is anticipated to grow with a vigorous CAGR of more than 9.20% over the forecast period 2024-2032. Hereditary angioedema, a rare but potentially life-threatening genetic disorder, manifests through sudden episodes of severe swelling in various parts of the body. As awareness increases and genetic screening becomes more prevalent, the demand for highly targeted therapies continues to rise. This has placed HAE at the forefront of innovation in the rare disease treatment landscape. Fueled by technological advancements and research collaborations, pharmaceutical companies are launching next-generation inhibitors that are transforming acute and prophylactic treatment paradigms.

The market's acceleration is driven by the evolution of treatment from conventional corticosteroids and antifibrinolytics to more refined and safer options such as C1-esterase inhibitors and kallikrein inhibitors. These agents offer improved efficacy with fewer side effects and longer half-lives, which drastically enhances patient quality of life and adherence. Furthermore, the introduction of oral medications as a replacement for intravenous or subcutaneous routes has widened access and reduced treatment burdens. This therapeutic shift reflects a broader industry trend toward personalization and convenience in chronic disease management, which resonates deeply with HAE patients managing lifelong conditions.

Parallel to therapeutic innovations, regulatory bodies have facilitated accelerated approvals of breakthrough drugs, catalyzing faster market penetration. Companies are strategically diversifying their product pipelines with both acute and prophylactic indications to cover a broader patient base. In addition, pricing strategies, patient assistance programs, and collaborations with rare disease advocacy groups are being actively leveraged to enhance market adoption. With a growing pediatric patient pool and increasing awareness among clinicians, there's a measurable uptick in early diagnosis rates, further bolstering the demand for long-term, well-tolerated therapies.

Regionally, North America dominates the HAE therapeutics market owing to early product availability, favorable reimbursement systems, and robust patient registries. The United States, in particular, demonstrates strong market penetration with widespread clinical trial activity and an established network of rare disease specialists. Europe follows closely behind, propelled by collaborative research frameworks and government support for orphan drug development. Meanwhile, Asia Pacific is expected to experience the highest growth rate, fueled by expanding healthcare infrastructure, rising rare disease literacy, and the ongoing rollout of genomic medicine in nations like Japan, South Korea, and India.

Major market player included in this report are:

CSL Behring
Takeda Pharmaceutical Company Limited
Pharming Group N.V.
BioCryst Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc.
Attune Pharmaceuticals, Inc.
Intellia Therapeutics, Inc.
Adverum Biotechnologies, Inc.
Arrowhead Pharmaceuticals, Inc.
HAE Therapeutics
Amgen Inc.
AstraZeneca
Regeneron Pharmaceuticals, Inc.
F. Hoffmann-La Roche Ltd.

The detailed segments and sub-segment of the market are explained below:

By Treatment Type

C-1 Esterase Inhibitor
Kallikrein Inhibitor

By Route of Administration

Oral
Parenteral

By Age Group

Pediatric
Adult

By Distribution Channel

Hospital Pharmacies
Online Pharmacies

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Years considered for the study are as follows:

Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Chapter 1. Global Hereditary Angioedema (HAE) Therapeutics Market Executive Summary

1.1. Global HAE Therapeutics Market Size & Forecast (2022 - 2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Treatment Type
- 1.3.2. By Route of Administration
- 1.3.3. By Age Group
- 1.3.4. By Distribution Channel
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global HAE Therapeutics Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Payer & Patient Perspectives)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory Frameworks & Orphan Designations
  - 2.3.4.2. Technological Advancements in Genetic Screening
  - 2.3.4.3. Patient Awareness & Advocacy
  - 2.3.4.4. Healthcare Infrastructure
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global HAE Therapeutics Market Dynamics

3.1. Market Drivers
- 3.1.1. Increased Awareness and Early Diagnosis of HAE
- 3.1.2. Advances in Targeted C1-Esterase and Kallikrein Inhibitors
- 3.1.3. Shift to Oral Therapies Reducing Treatment Burden
3.2. Market Challenges
- 3.2.1. High Treatment Costs and Reimbursement Constraints
- 3.2.2. Limited Access and Infrastructure in Emerging Markets
3.3. Market Opportunities
- 3.3.1. Rapid Growth in Asia-Pacific Rare Disease Markets
- 3.3.2. Development of Next-Generation Long-Acting Molecules
- 3.3.3. Expansion of Pediatric Indications and Prophylactic Use

Chapter 4. Global HAE Therapeutics Market Industry Analysis

4.1. Porter's Five Forces Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's Five Forces
- 4.1.7. Impact Analysis
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspectives
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global HAE Therapeutics Market Size & Forecasts by Treatment Type 2022 - 2032

5.1. Segment Dashboard
5.2. Global HAE Market: Treatment-Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1. C1-Esterase Inhibitor
- 5.2.2. Kallikrein Inhibitor

Chapter 6. Global HAE Therapeutics Market Size & Forecasts by Route of Administration 2022 - 2032

6.1. Segment Dashboard
6.2. Global HAE Market: Route-of-Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.2.1. Oral
- 6.2.2. Parenteral

Chapter 7. Global HAE Therapeutics Market Size & Forecasts by Age Group 2022 - 2032

7.1. Segment Dashboard
7.2. Global HAE Market: Age-Group Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 7.2.1. Pediatric
- 7.2.2. Adult

Chapter 8. Global HAE Therapeutics Market Size & Forecasts by Distribution Channel 2022 - 2032

8.1. Segment Dashboard
8.2. Global HAE Market: Distribution-Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 8.2.1. Hospital Pharmacies
- 8.2.2. Online Pharmacies

Chapter 9. Global HAE Therapeutics Market Size & Forecasts by Region 2022 - 2032

9.1. North America
- 9.1.1. U.S.
  - 9.1.1.1. Treatment-Type breakdown size & forecasts, 2022 - 2032
  - 9.1.1.2. Route-of-Administration breakdown size & forecasts, 2022 - 2032
- 9.1.2. Canada
9.2. Europe
- 9.2.1. UK
- 9.2.2. Germany
- 9.2.3. France
- 9.2.4. Spain
- 9.2.5. Italy
- 9.2.6. Rest of Europe
9.3. Asia Pacific
- 9.3.1. China
- 9.3.2. India
- 9.3.3. Japan
- 9.3.4. Australia
- 9.3.5. South Korea
- 9.3.6. Rest of Asia Pacific
9.4. Latin America
- 9.4.1. Brazil
- 9.4.2. Mexico
- 9.4.3. Rest of Latin America
9.5. Middle East & Africa
- 9.5.1. Saudi Arabia
- 9.5.2. South Africa
- 9.5.3. Rest of Middle East & Africa

Chapter 10. Competitive Intelligence

10.1. Key Company SWOT Analysis
- 10.1.1. CSL Behring
- 10.1.2. Takeda Pharmaceutical Company Limited
- 10.1.3. Pharming Group N.V.
10.2. Top Market Strategies
10.3. Company Profiles
- 10.3.1. CSL Behring
  - 10.3.1.1. Key Information
  - 10.3.1.2. Overview
  - 10.3.1.3. Financial (Subject to Data Availability)
  - 10.3.1.4. Product Summary
  - 10.3.1.5. Market Strategies
- 10.3.2. Takeda Pharmaceutical Company Limited
- 10.3.3. Pharming Group N.V.
- 10.3.4. BioCryst Pharmaceuticals, Inc.
- 10.3.5. Ionis Pharmaceuticals, Inc.
- 10.3.6. KalVista Pharmaceuticals, Inc.
- 10.3.7. Attune Pharmaceuticals, Inc.
- 10.3.8. Intellia Therapeutics, Inc.
- 10.3.9. Adverum Biotechnologies, Inc.
- 10.3.10. Arrowhead Pharmaceuticals, Inc.
- 10.3.11. HAE Therapeutics
- 10.3.12. Amgen Inc.
- 10.3.13. AstraZeneca
- 10.3.14. Regeneron Pharmaceuticals, Inc.
- 10.3.15. F. Hoffmann-La Roche Ltd.

Chapter 11. Research Process

11.1. Research Process
- 11.1.1. Data Mining
- 11.1.2. Analysis
- 11.1.3. Market Estimation
- 11.1.4. Validation
- 11.1.5. Publishing
11.2. Research Attributes